 Neoplasm, Residual
"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 0 | 3 | 3 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2010 | 0 | 3 | 3 | | 2012 | 2 | 1 | 3 | | 2013 | 1 | 2 | 3 | | 2014 | 0 | 3 | 3 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 2 | 2 | 4 | | 2018 | 2 | 3 | 5 | | 2019 | 3 | 6 | 9 | | 2020 | 2 | 3 | 5 | | 2021 | 0 | 8 | 8 | | 2022 | 0 | 7 | 7 | | 2023 | 0 | 2 | 2 | | 2024 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
-
Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2024 06 01; 109(6):1766-1778.
-
Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, Major A, Karrison T, Jiang K, Ramsland A, Kubicki T, Jakubowiak AJ. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
Winters AC, Pollyea DA. Molecular measurable residual disease: staring at red herrings. Haematologica. 2024 02 01; 109(2):371-373.
-
Rabin KR, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler JK, Yang JJ, Carroll AJ, Heerema NA, Borowitz MJ, Wood BL, Roberts KG, Mullighan CG, Harvey RC, Chen IM, Willman CL, Reshmi SC, Gastier-Foster JM, Bhojwani D, Rheingold SR, Maloney KW, Mattano LA, Larsen EC, Schore RJ, Burke MJ, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Loh ML, Hunger SP, Angiolillo AL. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
-
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 10 01; 108(10):2616-2625.
-
Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041.
-
Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park). 2022 10 07; 36(10):604-608.
-
Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
-
Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax?+?Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022 10; 28(10):694.e1-694.e9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|